The long saga of Avandia's disgrace is over. The FDA has lifted the final layer of safety measures on the GlaxoSmithKline ($GSK) diabetes drug, 8 years after researchers flagged an apparent increase in the risk of heart attack, and at least three years too late to make a difference in sales. The safety questions drove Avandia revenues down from a peak of $3 billion before the controversy to $183 million in 2011, just before generics hit the market.
In a safety communication Wednesday, the FDA said its "continued monitoring" of Avandia, Avandamet and Avandaryl had turned up "no new pertinent safety information" about the drug.
An outcry over those red flags--prompted by a meta-analysis published by the New England Journal of Medicine--spurred the agency to slap harsh limits on the drug in 2010. Those restrictions essentially shrank Avandia's market to the very few patients whose doctors were willing to brave the red tape necessary to write a script. European regulators withdrew the drug altogether.
Avandia sales plummeted from a $3 billion peak to $680 million in 2010, and GSK took a $2.4 billion charge that year to cover related litigation costs. As of February 2015, the company had settled most of the Avandia-related liability claims, GSK's annual report notes.
But in 2013, GlaxoSmithKline persuaded the FDA to take another look at the data on Avandia, citing concerns about how that study, known as Record, was designed. An FDA advisory panel met for two days to hash over the data and then voted to remove most of those restrictions.
The agency determined that the data didn't prove an increased risk of heart attack with Avandia and its combo meds, compared with the standard diabetes meds metformin and sulfonylurea.
The only additional precautions that remained were requirements for GSK (and any generics makers) to educate doctors and other prescribers about "the current state of knowledge" about Avandia's cardiovascular risks.
"Manufacturers have since fulfilled these requirements," the FDA said in Wednesday's notice, and the risk-management measures in place are "no longer necessary to ensure that the benefits of rosiglitazone medicines outweigh their risks."
The last time GSK disclosed the Avandia franchise's sales was 2012, when they amounted to £6 million, or about $9 million at today's exchange rates; that was a decline from £123 million ($183 million) in 2011. Generics had hit the market in the second quarter of 2012, siphoning away the brand's revenue.
- see the FDA notice
Special Reports: Top 15 pharma companies by 2014 revenue - GSK